COCP - コクリスタル・ファ―マ （Cocrystal Pharma Inc.） コクリスタル・ファ―マCOCPのチャート
COCPの企業情報
| symbol | COCP |
|---|---|
| 会社名 | Cocrystal Pharma Inc （コクリスタル・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Cocrystal Pharma Inc. is a clinical stage biotechnology company. The Company focuses on discovering and developing novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company focuses on developing and commercializing antiviral drug candidates for the treatment and prophylaxis of hepatitis C influenza and norovirus. The Company uses computational methods to screen and design product candidates using its cocrystal structural information. The Company’s Hepatitis C Virus (HCV) Non-Nucleoside Polymerase Inhibitor CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a novel PB2 inhibitor for the treatment of influenza infection. The Company is also focused on identifying and developing nucleoside and non-nucleoside polymerase inhibitors for the treatment of Norovirus infections. コクリスタル・ファ―マは米国の医薬品企業。主にヒトのウィルス性疾患の治療薬の開発に従事する。ウィルスの複製機能を阻害する抗ウィルス治療薬で、RNAポリメラ―ゼ酵素、ヘリカ―ゼ酵素、C型肝炎のNS5Aたんぱく質、インフルエンザウィルスやノロウィルスのRNAポリメラ―ゼを含む。同社は薬物レベルでの酵素相互作用に焦点を当てる。本社はジョ―ジア州タッカ―。 Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. |
| 本社所在地 | 1860 Montreal Road Tucker GA 30084 USA |
| 代表者氏名 | Raymond F. Schinazi レイモンドF.シナジー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 425-398-7178 |
| 設立年月日 | 39052 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 10人 |
| url | https://www.cocrystalpharma.com/ |
| nasdaq_url | https://www.nasdaq.com/symbol/cocp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -8.06300 |
| 終値（lastsale） | 2.725 |
| 時価総額（marketcap） | 81540382.1 |
| 時価総額 | 時価総額（百万ドル） 81.98923 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 75.14823 |
| 当期純利益 | 当期純利益（百万ドル） 0.04100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cocrystal Pharma Inc revenues was not reported. Net loss decreased 18% to $2.9M. Lower net loss reflects Research and development decrease of 40% to $2M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.15 to -$0.11. |
COCPのテクニカル分析
COCPのニュース
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors 2023/04/24 12:00:00 Cocrystal Pharma
We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
$2M Bet On Cocrystal Pharma? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying 2023/04/10 13:05:21 Benzinga
The Dow Jones closed slightly higher on Thursday. When insiders purchase or sell … Full story available on Benzinga.com
Cocrystal Pharma completes $4M private placement priced ATM 2023/04/10 13:03:30 Seeking Alpha
Cocrystal Pharma (COCP) has announced the completion of a private placement of 2.03M shares of common stock at a price of $1.97/share for proceeds of $4M.Through this private placement Dr
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules 2023/04/10 12:30:00 Cocrystal Pharma
We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Cocrystal Pharma GAAP EPS of -$4.77 2023/03/29 12:28:15 Seeking Alpha
Cocrystal Pharma press release (COCP): FY GAAP EPS of -$4.77.Cocrystal reported unrestricted cash of $37.1 million as of December 31, 2022 Net cash used in operating activities for…
Cocrystal Pharma GAAP EPS of -$4.77 2023/03/29 12:28:15 Seeking Alpha
Cocrystal Pharma press release (COCP): FY GAAP EPS of -$4.77.Cocrystal reported unrestricted cash of $37.1 million as of December 31, 2022 Net cash used in operating activities for…
Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A 2022/12/19 13:00:00 Cocrystal Pharma
We are a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of coronaviruses (including SARS-CoV-2), influenza viruses, noroviruses and hepatitis C viruses. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Cocrystal Pharma GAAP EPS of -$0.70 misses by $0.21 2022/11/14 13:48:40 Seeking Alpha
Cocrystal Pharma press release (COCP): Q3 GAAP EPS of -$0.70 misses by $0.21.Cocrystal reported unrestricted cash of $42.1 million as of September 30, 2022 compared with $58.7 million…
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs 2022/11/14 13:00:00 GlobeNewswire
BOTHELL, Wash., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the three and nine months ended September 30, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday 2022/11/03 09:40:43 Benzinga
Gainers Starry Group Holdings, Inc. (NYSE: STRY ) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. Benefitfocus, Inc. (NASDAQ: BNFT ) shares surged 48.2% to settle at $10.36 on Wednesday after the company announced it will be acquired by Voya Financial for $10.50 per share. Forza X1, Inc. (NASDAQ: FRZA ) climbed 45% to close at $2.45 after the company announced it received 50 electric boat reservations in the last 90 days, potentially resulting in over $8.5 million in revenue. Bandwidth Inc. (NASDAQ: BAND ) rose 41.6% to close at $17.42 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Rayonier Advanced Materials Inc. (NYSE: RYAM ) shares gained 34.2% to close at $6.00 as the company posted upbeat quarterly results. Chegg, Inc. (NYSE: CHGG ) gained 22% to close at $25.75 after the company reported better-than-expected Q3 results. The company also issued FY22 sales guidance above analyst estimates.
Cocrystal Pharma GAAP EPS of -$0.70 misses by $0.21 2022/11/14 13:48:40 Seeking Alpha
Cocrystal Pharma press release (COCP): Q3 GAAP EPS of -$0.70 misses by $0.21.Cocrystal reported unrestricted cash of $42.1 million as of September 30, 2022 compared with $58.7 million…
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs 2022/11/14 13:00:00 GlobeNewswire
BOTHELL, Wash., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the three and nine months ended September 30, 2022, and provides updates on its antiviral pipeline, upcoming milestones and business activities.
Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday 2022/11/03 09:40:43 Benzinga
Gainers Starry Group Holdings, Inc. (NYSE: STRY ) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results. Benefitfocus, Inc. (NASDAQ: BNFT ) shares surged 48.2% to settle at $10.36 on Wednesday after the company announced it will be acquired by Voya Financial for $10.50 per share. Forza X1, Inc. (NASDAQ: FRZA ) climbed 45% to close at $2.45 after the company announced it received 50 electric boat reservations in the last 90 days, potentially resulting in over $8.5 million in revenue. Bandwidth Inc. (NASDAQ: BAND ) rose 41.6% to close at $17.42 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Rayonier Advanced Materials Inc. (NYSE: RYAM ) shares gained 34.2% to close at $6.00 as the company posted upbeat quarterly results. Chegg, Inc. (NYSE: CHGG ) gained 22% to close at $25.75 after the company reported better-than-expected Q3 results. The company also issued FY22 sales guidance above analyst estimates.
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday''s Mid-Day Session 2022/11/02 17:28:02 Benzinga
Gainers Starry Group Holdings, Inc. (NYSE: STRY ) gained 56% to $0.2808 after reporting Q3 results. Benefitfocus, Inc. (NASDAQ: BNFT ) shares jumped 47.8% to $10.33 after the company announced it will be acquired by Voya Financial for $10.50 per share. Akso Health Group (NASDAQ: AHG ) gained 44% to $0.7280. Rayonier Advanced Materials Inc. (NYSE: RYAM ) shares climbed 40.9% to $6.30 as the company posted upbeat quarterly results. Forza X1, Inc. (NASDAQ: FRZA ) jumped 39% to $2.3495 after the company announced it received 50 electric boat reservations in the last 90 days, potentially resulting in over $8.5 million in revenue. Bandwidth Inc. (NASDAQ: BAND ) gained 36.9% to $16.84 after the company reported better-than-expected Q3 sales results. The company also issued Q4 and FY22 sales guidance above analyst estimates. Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) shares rose 32.8% to $24.30 after the company announced collaboration with CSL to develop and commercialize self-amplifying mRNA vaccines.